VERS.L Regulatory News (VERS)

Verseon Corporation

("Verseon" or the "Company")

Announcement of Special Shareholder Meeting and Change of Directors

FREMONT, Calif.-Verseon Corporation (AIM:VSN), a technology-based pharmaceutical company, is pleased to announce that Dr. Robert Karr has accepted the nomination for a position on the Verseon Board of Directors. His appointment is subject to approval at a Special Shareholder Meeting ("Special Meeting") for the election of a Class II Director, which will be held at 7100 Stevenson Blvd, Fremont, CA 94538 on October 19, 2017 at 2 p.m. local time, and the completion of customary UK regulatory requirements. Alastair Cade, a Class II Non-Executive Director of the Company, has stepped down from his position on the Board of Directors with immediate effect.

Dr. Robert Karr, the former Senior Vice President of R&D Strategy at Pfizer, is currently the Chief Scientific Officer at Tioma, an immuno-oncology company developing antibody treatments for solid and hematologic cancers. During his extensive career in the pharmaceutical industry, Dr. Karr has held various senior executive positions at Idera Pharmaceuticals, Pfizer, and Warner-Lambert. Prior to his career in industry, Dr. Karr completed his internship, residency, and fellowship at Washington University School of Medicine and held a faculty position at University of Iowa College of Medicine.

Copies of the following Special Meeting documents will be available to view and download between September 25 and October 19, 2017 from the Company's website at: http://www.verseon.com/investor-notices/ssm2017-10-19:

· Notice of Special Shareholder Meeting

· Special Shareholder Meeting Proxy Information Statement

A further update regarding the appointment of Dr. Karr will be provided on or around October 19, 2017.

- Ends -

For further information, please contact

For financial and business media enquiries, please contact

For trade and pharma media enquiries, please contact